Cart
sales@molnova.com
VMY-1-103
CAS No. 1209002-43-6
VMY-1-103 ( VMY 1-103 )
Catalog No. M10779 CAS No. 1209002-43-6
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameVMY-1-103
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
-
DescriptionA novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B; increases the sub G(1) fraction of apoptotic cells, induces PARP and caspase-3 cleavage and increases the levels of the death receptors DR4 and DR5, Bax and Bad.
-
SynonymsVMY 1-103
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1209002-43-6
-
Formula Weight708.27
-
Molecular FormulaC34H42ClN9O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCNS(=O)(C1=C2C=CC=C(N(C)C)C2=CC=C1)=O)C3=CC=C(NC4=C5N=CN(C(C)C)C5=NC(N[C@H](C(C)C)CO)=N4)C=C3Cl
-
Chemical Name2-Chloro-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ringer L, et al. Cancer Biol Ther. 2011 Nov 1;12(9):818-26.
2. Sirajuddin P, et al. Cell Cycle. 2012 Oct 15;11(20):3801-9.
3. Waye S, et al. Aging (Albany NY). 2015 Oct;7(10):854-68.
2. Sirajuddin P, et al. Cell Cycle. 2012 Oct 15;11(20):3801-9.
3. Waye S, et al. Aging (Albany NY). 2015 Oct;7(10):854-68.
molnova catalog
related products
-
LY2857785
LY2857785 is a potenrt, reversible and ATP-competitive CDK9 inhibitor with IC50 of 11 nM, also inhibits CDK8 (IC50=16 nM) and weakly inhibits CSK7 (IC50=246 nM).
-
PF-00562271
PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM.
-
SEL120-34A hydrochlo...
SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.
